Psutka SP - Search Results

1

Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019.

Psutka SP, Chang SL, Cahn D, Uzzo RG, McGregor BA. Psutka SP, et al. Am Soc Clin Oncol Educ Book. 2019 Jan;39:276-283. doi: 10.1200/EDBK_237453. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099657 Free article. Review.

2

Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series.

Gershman B, Psutka SP, Matsumoto JM, King BF, Kawashima A, Morris JM, Leibovich BC. Gershman B, et al. Among authors: psutka sp. Urol Pract. 2016 Mar;3(2):124-133. doi: 10.1016/j.urpr.2015.05.008. Epub 2015 Dec 21. Urol Pract. 2016. PMID: 37592473

3

Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.

Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Psutka SP, et al. Eur Urol. 2013 Mar;63(3):486-92. doi: 10.1016/j.eururo.2012.08.062. Epub 2012 Sep 5. Eur Urol. 2013. PMID: 22959191

4

The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization.

Psutka SP, Kim SP, Gross CP, Van Houten H, Thompson RH, Abouassaly R, Weight C, Boorjian SA, Leibovich BC, Shah ND. Psutka SP, et al. Urology. 2015 Feb;85(2):442-50. doi: 10.1016/j.urology.2014.10.040. Urology. 2015. PMID: 25623717

5

Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.

Psutka SP, Heidenreich M, Boorjian SA, Bailey GC, Cheville JC, Stewart-Merrill SB, Lohse CM, Atwell TD, Costello BA, Leibovich BC, Thompson RH. Psutka SP, et al. BJU Int. 2017 Jan;119(1):116-127. doi: 10.1111/bju.13620. Epub 2016 Aug 31. BJU Int. 2017. PMID: 27489013

6

Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort.

Chen VS, Abouassaly R, Gonzalez CM, Kutikov A, Smaldone MC, Meropol NJ, Psutka SP, Williams SB, O'Malley R, Sedlacek HM, Kim SP. Chen VS, et al. Among authors: psutka sp. Urol Oncol. 2017 Nov;35(11):662.e17-662.e21. doi: 10.1016/j.urolonc.2017.07.011. Epub 2017 Aug 7. Urol Oncol. 2017. PMID: 28781110

7

Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma.

Psutka SP. Psutka SP. Cancer. 2020 Sep 1;126(17):3912-3915. doi: 10.1002/cncr.32993. Epub 2020 Jun 9. Cancer. 2020. PMID: 32515836 Free article. No abstract available.

8

Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.

Higgins MI, Martini DJ, Patil DH, Nabavizadeh R, Steele S, Williams M, Joshi SS, Narayan VM, Sekhar A, Psutka SP, Ogan K, Bilen MA, Master VA. Higgins MI, et al. Among authors: psutka sp. Cancer. 2021 Jun 15;127(12):1974-1983. doi: 10.1002/cncr.33462. Epub 2021 Mar 24. Cancer. 2021. PMID: 33760232 Free article.

9

Metastasectomy in kidney cancer: current indications and treatment approaches.

Prunty M, Bukavina L, Psutka SP. Prunty M, et al. Among authors: psutka sp. Curr Opin Support Palliat Care. 2021 Dec 1;15(4):266-275. doi: 10.1097/SPC.0000000000000574. Curr Opin Support Palliat Care. 2021. PMID: 34610626 Review.

10

Muscle Mass Matters in Patients with Renal Cell Carcinoma, but That Is Only the Beginning….

Psutka SP. Psutka SP. Ann Surg Oncol. 2022 Apr;29(4):2152-2154. doi: 10.1245/s10434-021-11091-x. Epub 2022 Jan 9. Ann Surg Oncol. 2022. PMID: 35000076 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters